<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00403910</url>
  </required_header>
  <id_info>
    <org_study_id>17</org_study_id>
    <nct_id>NCT00403910</nct_id>
  </id_info>
  <brief_title>Antiremodeling Effect Of Aldosterone Receptors Blockade With Canrenone In Mild Chronic Heart Failure. AREA IN-CHF Study</brief_title>
  <official_title>Phase 3 Study Of Antiremodeling Effect Of Aldosterone Receptors Blockade With Canrenone In Mild Chronic Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heart Care Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heart Care Foundation</source>
  <brief_summary>
    <textblock>
      The RALES study has shown that spironolactone reduces the risk of morbidity and mortality
      both from progressive heart failure and sudden death, in patients with NYHA III or IV heart
      failure. This favourable effect was clearly independent from a diuretic effect.
      Antialdosterone drugs may be effective because they opposes the effects of aldosterone on
      sodium retention, loss of magnesium and potassium, sympathetic activation, baroreceptor
      function and vascular compliance. Antialdosterone treatment may also antagonize the effect of
      aldosterone in promoting cardiac fibrosis. In a RALES substudy baseline serum PIIINP, a
      marker of cardiac fibrosis synthesis showed an independent negative correlation with survival
      and CHF hospitalizations in the placebo group. Therefore it seems interesting to evaluate the
      effect of an Aldosterone receptor blocker on progression of left ventricular dysfunction in
      patients with mild heart failure assuming standard therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The protocol is sponsored by and independent organization and partially supported by Therabel
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2002</start_date>
  <completion_date>July 2006</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in echocardiographic left ventricular diastolic volume</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in left ventricular systolic volume</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in ejection fraction</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in NYHA class</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiac mortality</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hospitalization for cardiac causes</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>combination of cardiac mortality hospitalizations for cardiac causes</measure>
  </secondary_outcome>
  <enrollment>500</enrollment>
  <condition>Heart Failure</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Canrenone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Established diagnosis of congestive heart failure in NYHA class II

          -  Left ventricular ejection fraction &lt;= 45% measured within 6 months from enrolment

          -  Stable standard heart failure therapy (if patients are on beta blocker drugs,
             treatment must have been started at least three months before enrolment)

          -  Informed consent (obtained prior of any study procedures)

        Exclusion Criteria:

          -  Age &lt;18 and &gt;80

          -  Serum creatinine level &gt; 2.5 mg per deciliter

          -  Serum potassium level &gt; 5.0 mmol per liter

          -  Valvular heart disease amenable to surgical treatment

          -  Congenital heart disease

          -  Unstable angina and/or acute myocardial infarction and/or coronary revascularization
             procedure within three months before enrolment

          -  Intravenous therapy with inotropic drugs within three months before enrolment

          -  History of resuscitated ventricular fibrillation or tachycardia, unless these occurred
             within 24 hours of an acute myocardial infarction or the subject has an implanted an
             automatic cardioverter defibrillator

          -  Chronic active hepatitis or cirrhosis

          -  Malignant neoplasm or any life threatening non cardiac disease

          -  History of hypersensitivity to study drug

          -  Pregnancy or lactating or childbearing age women who are not protected by an accepted
             method of contraception

          -  History of drug or alcohol abuse

          -  Legal incapacity and/or other circumstances rending the patient unable to understand
             the nature, scope and possible consequences of the study.

          -  Evidence of uncooperative attitude

          -  Any condition other than heart failure that does not permit an optimal participation
             to the trial

          -  Participation to other RCTs during the last 3 months

          -  Treatment with: Lithium salts, Potassium sparing diuretics, oral positive inotropic
             drugs or any investigational drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alessandro Boccanelli, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Ospedale San Giovanni di Roma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Presidio GM Lancisi</name>
      <address>
        <city>Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az Ospedaliera Giuseppe Moscati</name>
      <address>
        <city>Avellino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presidio Ospedaliero Moscati</name>
      <address>
        <city>Aversa (CE)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Monsignor Angelo R di Miccoli</name>
      <address>
        <city>Barletta (BA)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti</name>
      <address>
        <city>Bergamo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiologia Tiarini Corticella</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Generale Provinciale</name>
      <address>
        <city>Bolzano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az Osp G Brotzu - S Michele</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az Ospedaliera S Anna e S Sebastiano</name>
      <address>
        <city>Caserta</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele G Giglio</name>
      <address>
        <city>Cefal√π (PA)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile San Giuseppe</name>
      <address>
        <city>Empoli (FI)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Maria del Prato</name>
      <address>
        <city>Feltre</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile Dario Camberlingo</name>
      <address>
        <city>Francavilla Fontana (BR)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az Osp-Univ San Martino</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile</name>
      <address>
        <city>Ivrea</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Fatebenefratelli</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hepseria Hospital Modena SPA</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Policlinico</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Evangelica Betania</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale V Cervello</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presidio Ospedaliero di Passirana</name>
      <address>
        <city>Passirana Rho (MI)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Policlinico S Matteo IRCCS</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Perugia</name>
      <address>
        <city>Perugia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale della val di nievole</name>
      <address>
        <city>pescia (PT)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda CREAS - IFC CNR San Cartaldo</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Generale Provinciale Lotti</name>
      <address>
        <city>Pontedera (PT)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile</name>
      <address>
        <city>Ragusa (RG)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Infermi</name>
      <address>
        <city>Rimini</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Camillo</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Sant'Andrea</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Santo Spirito</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Luigi di Liegro</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az Osp San Giovanni di Dio e Ruggi d'Aragona</name>
      <address>
        <city>Salerno</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale G Fra Cristoforo</name>
      <address>
        <city>San Bonifacio (VR)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale casa Sollievo della Sofferenza</name>
      <address>
        <city>San Giovanni Rotondo (FG)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presidio Ospedaliero di Saronno</name>
      <address>
        <city>Saronno</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Bartolomeo</name>
      <address>
        <city>Sarzana (GE)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale SS Annunziata</name>
      <address>
        <city>Sassari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Policlinico Multimedica</name>
      <address>
        <city>Sesto San Giovanni</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione S Maugeri Clinica del Lavoro</name>
      <address>
        <city>Telese Terme (BN)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Cardinale Panico</name>
      <address>
        <city>Tricase (LE)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az Osp-Univ Ospdali Riuniti</name>
      <address>
        <city>Trieste</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Luca</name>
      <address>
        <city>Vallo della Lucania (SA)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Circolo e Fondazione Macchi</name>
      <address>
        <city>Varese</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedali Civili Riuniti</name>
      <address>
        <city>Venezia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.anmco.it</url>
  </link>
  <reference>
    <citation>Cacciatore G, Boccanelli A, Mureddu GF, Maggioni AP, Latini R, Masson S, de Simone G; Investigatori dell' Area In-CHF. [The AREA IN-CHF trial (antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure): rationale and design]. Ital Heart J. 2005 May;6 Suppl 1:66S-74S. Review. Italian.</citation>
    <PMID>15945301</PMID>
  </reference>
  <results_reference>
    <citation>Boccanelli A, Mureddu GF, Cacciatore G, Clemenza F, Di Lenarda A, Gavazzi A, Porcu M, Latini R, Lucci D, Maggioni AP, Masson S, Vanasia M, de Simone G; AREA IN-CHF Investigators. Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results. Eur J Heart Fail. 2009 Jan;11(1):68-76. doi: 10.1093/eurjhf/hfn015.</citation>
    <PMID>19147459</PMID>
  </results_reference>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2006</study_first_submitted>
  <study_first_submitted_qc>November 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2006</study_first_posted>
  <last_update_submitted>April 16, 2009</last_update_submitted>
  <last_update_submitted_qc>April 16, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 17, 2009</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Canrenone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

